Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 4 October 1991:
Vol. 254. no. 5028, pp. 105 - 108
DOI: 10.1126/science.1718036
Prev | Table of Contents | Next

Articles

Science, Vol 254, Issue 5028, 105-108
Copyright © 1991 by American Association for the Advancement of Science

articles

Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120

KS Steimer, CJ Scandella, PV Skiles, and NL Haigwood

Chiron Corporation, Emeryville, CA 94608.

The spectrum of human immunodeficiency virus type 1 (HIV-1) isolates neutralized by antibodies from HIV-1-infected humans is broader than the spectrum of isolates neutralized by sera from animals immunized with purified gp120 subunits. This broader neutralization was due, in part, to the presence of antibodies to conserved gp120 conformational epitopes. Purified conformation-dependent gp120-specific human antibodies neutralized a wider range of virus isolates than human antibodies directed to linear determinants in gp120 and were also responsible for the majority of the gp120-specific CD4-blocking activity of HIV-1-infected human sera. A gp120 subunit vaccine that effectively presents these conformation-dependent neutralization epitopes should protect against a broader range of HIV-1 variants than a vaccine that presents exclusively linear determinants.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques.
W.M. Blay, S. Gnanakaran, B. Foley, N. A. Doria-Rose, B. T. Korber, and N. L. Haigwood (2006)
J. Virol. 80, 999-1014
   Abstract »    Full Text »    PDF »
Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope.
N. A. Doria-Rose, G. H. Learn, A. G. Rodrigo, D. C. Nickle, F. Li, M. Mahalanabis, M. T. Hensel, S. McLaughlin, P. F. Edmonson, D. Montefiori, et al. (2005)
J. Virol. 79, 11214-11224
   Abstract »    Full Text »    PDF »
Glycosylation of Immunodominant Linear Epitopes in the Carboxy-Terminal Region of the Caprine Arthritis-Encephalitis Virus Surface Envelope Enhances Vaccine-Induced Type-Specific and Cross-Reactive Neutralizing Antibody Responses.
J. D. Trujillo, N. M. Kumpula-McWhirter, K. J. Hotzel, M. Gonzalez, and W. P. Cheevers (2004)
J. Virol. 78, 9190-9202
   Abstract »    Full Text »    PDF »
Passive Immunotherapy in Simian Immunodeficiency Virus-Infected Macaques Accelerates the Development of Neutralizing Antibodies.
N. L. Haigwood, D. C. Montefiori, W. F. Sutton, J. McClure, A. J. Watson, G. Voss, V. M. Hirsch, B. A. Richardson, N. L. Letvin, S.-L. Hu, et al. (2004)
J. Virol. 78, 5983-5995
   Abstract »    Full Text »    PDF »
Covalently Linked Human Immunodeficiency Virus Type 1 gp120/gp41 Is Stably Anchored in Rhabdovirus Particles and Exposes Critical Neutralizing Epitopes.
P. M. McKenna, R. J. Pomerantz, B. Dietzschold, J. P. McGettigan, and M. J. Schnell (2003)
J. Virol. 77, 12782-12794
   Abstract »    Full Text »    PDF »
Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate.
I. K. Srivastava, L. Stamatatos, E. Kan, M. Vajdy, Y. Lian, S. Hilt, L. Martin, C. Vita, P. Zhu, K. H. Roux, et al. (2003)
J. Virol. 77, 11244-11259
   Abstract »    Full Text »    PDF »
HIV Mucosal Vaccine: Nasal Immunization with gp160-Encapsulated Hemagglutinating Virus of Japan-Liposome Induces Antigen-Specific CTLs and Neutralizing Antibody Responses.
G. Sakaue, T. Hiroi, Y. Nakagawa, K. Someya, K. Iwatani, Y. Sawa, H. Takahashi, M. Honda, J. Kunisawa, and H. Kiyono (2003)
J. Immunol. 170, 495-502
   Abstract »    Full Text »    PDF »
Mutagenic Stabilization and/or Disruption of a CD4-Bound State Reveals Distinct Conformations of the Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein.
S.-H. Xiang, P. D. Kwong, R. Gupta, C. D. Rizzuto, D. J. Casper, R. Wyatt, L. Wang, W. A. Hendrickson, M. L. Doyle, and J. Sodroski (2002)
J. Virol. 76, 9888-9899
   Abstract »    Full Text »    PDF »
Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization.
B. K. Chakrabarti, W.-p. Kong, B.-y. Wu, Z.-Y. Yang, J. Friborg, X. Ling, S. R. King, D. C. Montefiori, and G. J. Nabel (2002)
J. Virol. 76, 5357-5368
   Abstract »    Full Text »    PDF »
Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins.
C. Grundner, T. Mirzabekov, J. Sodroski, and R. Wyatt (2002)
J. Virol. 76, 3511-3521
   Abstract »    Full Text »    PDF »
Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus.
I. K. Srivastava, L. Stamatatos, H. Legg, E. Kan, A. Fong, S. R. Coates, L. Leung, M. Wininger, J. J. Donnelly, J. B. Ulmer, et al. (2002)
J. Virol. 76, 2835-2847
   Abstract »    Full Text »    PDF »
A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response.
P. F. Zhang, P. Bouma, E. J. Park, J. B. Margolick, J. E. Robinson, S. Zolla-Pazner, M. N. Flora, and G. V. Quinnan Jr (2002)
J. Virol. 76, 644-655
   Abstract »    Full Text »    PDF »
HIV Mucosal Vaccine: Nasal Immunization with rBCG-V3J1 Induces a Long Term V3J1 Peptide-Specific Neutralizing Immunity in Th1- and Th2-Deficient Conditions.
T. Hiroi, H. Goto, K. Someya, M. Yanagita, M. Honda, N. Yamanaka, and H. Kiyono (2001)
J. Immunol. 167, 5862-5867
   Abstract »    Full Text »    PDF »
Induction and Characterization of Neutralizing Antibodies against a Human Immunodeficiency Virus Type 1 Primary Isolate.
C.-H. Chen, L. Jin, C. Zhu, S. Holz-Smith, and T. J. Matthews (2001)
J. Virol. 75, 6700-6704
   Abstract »    Full Text »
Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers.
X. Yang, R. Wyatt, and J. Sodroski (2001)
J. Virol. 75, 1165-1171
   Abstract »    Full Text »
Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140.
P. L. Earl, W. Sugiura, D. C. Montefiori, C. C. Broder, S. A. Lee, C. Wild, J. Lifson, and B. Moss (2001)
J. Virol. 75, 645-653
   Abstract »    Full Text »
The N-Terminal V3 Loop Glycan Modulates the Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors.
S. E. Malenbaum, D. Yang, L. Cavacini, M. Posner, J. Robinson, and C. Cheng-Mayer (2000)
J. Virol. 74, 11008-11016
   Abstract »    Full Text »
Human Immunodeficiency Virus: An Epidemic without Precedent.
A. J. AMMANN (2000)
Ann. N.Y. Acad. Sci. 918, 3-8
   Full Text »    PDF »
Human neutralizing human immunodeficiency virustype 2-specific Fab molecules generated by phage display.
E. Björling, E. von Garrelts, A. Mörner, M. Ehnlund, and M. A. A. Persson (1999)
J. Gen. Virol. 80, 1987-1993
   Abstract »    Full Text »
Both Neutralization Resistance and High Infectivity Phenotypes Are Caused by Mutations of Interacting Residues in the Human Immunodeficiency Virus Type 1 gp41 Leucine Zipper and the gp120 Receptor- and Coreceptor-Binding Domains.
E. J. Park and G. V. Quinnan Jr. (1999)
J. Virol. 73, 5707-5713
   Abstract »    Full Text »
Cross-Subtype Neutralizing Antibodies Induced in Baboons by a Subtype E gp120 Immunogen Based on an R5 Primary Human Immunodeficiency Virus Type 1 Envelope.
T. C. VanCott, J. R. Mascola, L. D. Loomis-Price, F. Sinangil, N. Zitomersky, J. McNeil, M. L. Robb, D. L. Birx, and S. Barnett (1999)
J. Virol. 73, 4640-4650
   Abstract »    Full Text »
Comparison of Immunity Generated by Nucleic Acid-, MF59-, and ISCOM-Formulated Human Immunodeficiency Virus Type 1 Vaccines in Rhesus Macaques: Evidence for Viral Clearance.
E. J. Verschoor, P. Mooij, H. Oostermeijer, M. van der Kolk, P. ten Haaft, B. Verstrepen, Y. Sun, B. Morein, L. Åkerblom, D. H. Fuller, et al. (1999)
J. Virol. 73, 3292-3300
   Abstract »    Full Text »
Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140.
N. M. Stamatos, J. R. Mascola, V. S. Kalyanaraman, M. K. Louder, L. M. Frampton, D. L. Birx, and T. C. VanCott (1998)
J. Virol. 72, 9656-9667
   Abstract »    Full Text »    PDF »
Study of the V3 Loop as a Target Epitope for Antibodies Involved in the Neutralization of Primary Isolates versus T-Cell-Line-Adapted Strains of Human Immunodeficiency Virus Type 1.
C. Spenlehauer, S. Saragosti, H. J. A. Fleury, A. Kirn, A.-M. Aubertin, and C. Moog (1998)
J. Virol. 72, 9855-9864
   Abstract »    Full Text »    PDF »
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens.
R. Wyatt and J. Sodroski (1998)
Science 280, 1884-1888
   Abstract »    Full Text »
Characterization of V3 Loop-Pseudomonas Exotoxin Chimeras. CANDIDATE VACCINES FOR HUMAN IMMUNODEFICIENCY VIRUS-1.
D. J. FitzGerald, C. M. Fryling, M. L. McKee, J. C. Vennari, T. Wrin, M. E. M. Cromwell, A. L. Daugherty, and R. J. Mrsny (1998)
J. Biol. Chem. 273, 9951-9958
   Abstract »    Full Text »    PDF »
Induction of Neutralizing Antibodies to T-Cell Line-Adapted and Primary Human Immunodeficiency Virus Type 1 Isolates with a Prime-Boost Vaccine Regimen in Chimpanzees.
S. Zolla-Pazner, M. Lubeck, S. Xu, S. Burda, R. J. Natuk, F. Sinangil, K. Steimer, R. C. Gallo, J. W. Eichberg, T. Matthews, et al. (1998)
J. Virol. 72, 1052-1059
   Abstract »    Full Text »    PDF »
Simian Immunodeficiency Virus (SIV) Envelope-Specific Fabs with High-Level Homologous Neutralizing Activity: Recovery from a Long-Term-Nonprogressor SIV-Infected Macaque.
J. Glamann, D. R. Burton, P. W. H. I. Parren, H. J. Ditzel, K. A. Kent, C. Arnold, D. Montefiori, and V. M. Hirsch (1998)
J. Virol. 72, 585-592
   Abstract »    Full Text »    PDF »
Structure and Polymorphism of HIV-1 Third Variable Loops.
P. Catasti, E. M. Bradbury, and G. Gupta (1996)
J. Biol. Chem. 271, 8236-8242
   Abstract »    Full Text »    PDF »
Candidate AIDS Vaccines.
B. S. Graham and P. F. Wright (1995)
N. Engl. J. Med. 333, 1331-1339
   Full Text »    PDF »
Scientific and social issues of human immunodeficiency virus vaccine development.
B. Haynes (1993)
Science 260, 1279-1286
   Abstract »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)